Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Kaye

Showing results (721-730 of 740) with videos related to

Pageof 74
Sort By:
Antimicrobial Agents and Chemotherapy|June 12, 2013
Epidemiology and risk factors for isolation of Escherichia coli producing CTX-M-type extended-spectrum β-lactamase in a large U.S. Medical CenterKayoko Hayakawa, Sureka Gattu, Dror Marchaim, et al.
NEJM Evidence|August 4, 2023
Colistin Monotherapy versus Combination Therapy for Carbapenem-Resistant OrganismsKeith S Kaye, Dror Marchaim, Visanu Thamlikitkul, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|November 5, 2016
Proposed primary endpoints for use in clinical trials that compare treatment options for bloodstream infection in adults: a consensus definitionP N A Harris, J F McNamara, D C Lye, et al.
Antimicrobial Agents and Chemotherapy|October 17, 2012
Epidemiology of vancomycin-resistant Enterococcus faecalis: a case-case-control studyKayoko Hayakawa, Dror Marchaim, Mohan Palla, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 19, 2025
The Impact of Synergistic Therapy Between Colistin and Meropenem on Outcomes of Patients With Pneumonia or Bloodstream Infection Due to Carbapenem-Resistant Gram-Negative PathogensMariya Huralska, Jason M Pogue, Michael Rybak, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|June 6, 2026
The Impact of Colistin MIC on Clinical Failure and Mortality: Insights from the OVERCOME TrialJason M Pogue, Michael J Rybak, Jacinda C Abdul-Mutakabbir, et al.
Antimicrobial Agents and Chemotherapy|May 15, 2026
Resistance to novel β-lactam/β-lactamase inhibitors among carbapenem-resistant <i>Pseudomonas aeruginosa</i> and clinical implications in the prospective observational <i>Pseudomonas</i> studyLee S Gottesdiener, Yixuan Li, Kerryl E Greenwood-Quaintance, et al.
The Lancet. Infectious Diseases|March 11, 2020
Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort studyDavid van Duin, Cesar A Arias, Lauren Komarow, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2005
3rd International Ovarian Cancer Consensus Conference: outstanding issues for future considerationG Stuart, E Avall-Lundqvist, A du Bois, et al.
American Journal of Infection Control|August 4, 2014
A Compendium of Strategies to Prevent Healthcare-Associated Infections in Acute Care Hospitals: 2014 UpdatesDeborah S Yokoe, Deverick J Anderson, Sean M Berenholtz, et al.
Pageof 74

Showing results (721-730 of 740) with videos related to

Sort By:
Pageof 74
Antimicrobial Agents and Chemotherapy|June 12, 2013
Epidemiology and risk factors for isolation of Escherichia coli producing CTX-M-type extended-spectrum β-lactamase in a large U.S. Medical CenterKayoko Hayakawa, Sureka Gattu, Dror Marchaim, et al.
NEJM Evidence|August 4, 2023
Colistin Monotherapy versus Combination Therapy for Carbapenem-Resistant OrganismsKeith S Kaye, Dror Marchaim, Visanu Thamlikitkul, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|November 5, 2016
Proposed primary endpoints for use in clinical trials that compare treatment options for bloodstream infection in adults: a consensus definitionP N A Harris, J F McNamara, D C Lye, et al.
Antimicrobial Agents and Chemotherapy|October 17, 2012
Epidemiology of vancomycin-resistant Enterococcus faecalis: a case-case-control studyKayoko Hayakawa, Dror Marchaim, Mohan Palla, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 19, 2025
The Impact of Synergistic Therapy Between Colistin and Meropenem on Outcomes of Patients With Pneumonia or Bloodstream Infection Due to Carbapenem-Resistant Gram-Negative PathogensMariya Huralska, Jason M Pogue, Michael Rybak, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|June 6, 2026
The Impact of Colistin MIC on Clinical Failure and Mortality: Insights from the OVERCOME TrialJason M Pogue, Michael J Rybak, Jacinda C Abdul-Mutakabbir, et al.
Antimicrobial Agents and Chemotherapy|May 15, 2026
Resistance to novel β-lactam/β-lactamase inhibitors among carbapenem-resistant <i>Pseudomonas aeruginosa</i> and clinical implications in the prospective observational <i>Pseudomonas</i> studyLee S Gottesdiener, Yixuan Li, Kerryl E Greenwood-Quaintance, et al.
The Lancet. Infectious Diseases|March 11, 2020
Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort studyDavid van Duin, Cesar A Arias, Lauren Komarow, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2005
3rd International Ovarian Cancer Consensus Conference: outstanding issues for future considerationG Stuart, E Avall-Lundqvist, A du Bois, et al.
American Journal of Infection Control|August 4, 2014
A Compendium of Strategies to Prevent Healthcare-Associated Infections in Acute Care Hospitals: 2014 UpdatesDeborah S Yokoe, Deverick J Anderson, Sean M Berenholtz, et al.
Pageof 74